Related Experiment Videos
An evidence-based disease-management program for patients with diabetic nephropathy
Afschin Gandjour1, Karl Wilhelm Lauterbach
1Institute of Health Economics and Clinical Epidemiology, University of Cologne, Cologne, Germany. afschin.gandjour@medizin.uni-koeln.de
Journal of Nephrology
|December 31, 2003
Summary
A new disease management program for diabetic nephropathy in Germany recommends clinical guidelines for early stages and specialist care for predialysis patients. Future research is needed for non-dialysis patient management tools.
Area of Science:
- Nephrology
- Diabetology
- Health Services Research
Background:
- Germany anticipates a significant increase in dialysis patients within the next decade.
- Diabetic nephropathy is a leading cause of end-stage renal disease.
- Effective disease management is crucial to mitigate this growing healthcare burden.
Purpose of the Study:
- To develop an evidence-based disease management program for diabetic nephropathy.
- To identify research gaps in disease management tools for this patient population.
Main Methods:
- Systematic literature search (1966-2001) on disease management tools and outcomes in diabetic nephropathy.
- Categorization of studies by scientific evidence level.
- Inclusion of expert judgment where scientific evidence was limited.
Main Results:
- Ten studies informed the program's recommendations.
- Recommendations include clinical guidelines, patient feedback, and documentation for early-stage nephropathy.
- Specialist coordination, educational sessions, case managers, and quality circles are advised for predialysis and dialysis patients.
- Cost-saving potential is highest for predialysis patient management.
Conclusions:
- Evidence for many disease management tools, particularly for non-dialysis patients, is lacking.
- The program can be initiated with predialysis patients to manage costs effectively.
- Further research is essential to optimize care for all stages of diabetic nephropathy.